Ipsc Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Induced pluripotent stem cell (iPSC) therapy represents a transformative approach in regenerative neurology. iPSCs are generated by reprogramming adult somatic cells (typically skin fibroblasts or blood cells) back to a pluripotent state, then differentiating them into the desired neural cell types. This technology enables patient-specific, personalized cell therapies and provides powerful disease modeling platforms. [1]
| Feature | iPSC | ESC | Fetal NSC | Adult NSC | [2]
|---------|------|-----|-----------|-----------| [3]
| Autologous possible | Yes | No | Rare | Sometimes | [4]
| Unlimited source | Yes | Yes | Limited | Limited |
| Tumor risk | Medium | High | Low | Low |
| Immune rejection | Low (auto) | High | Medium | Medium |
| Differentiation | Comprehensive | Comprehensive | Limited | Limited |
| Cost | High | Medium | Low | Low |
The study of Ipsc Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Barker RA, et al. Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease. 2019. ↩︎
Chen KG, et al. Clinical-grade human iPSC for disease modeling and regenerative therapy. 2021. ↩︎
Doi D, et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell surface markers. 2020. ↩︎
Avior Y, et al. Pluripotent stem cells in neurodegenerative disease therapy and disease modeling. 2022. ↩︎